Harry J Long

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Prevention, diagnosis, and treatment of cervical cancer
    Harry J Long
    Division of Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:1566-74. 2007
  2. ncbi Management of metastatic cervical cancer: review of the literature
    Harry J Long
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA
    J Clin Oncol 25:2966-74. 2007
  3. ncbi Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study
    Harry J Long
    Mayo Clinic, Department of Medical Oncology, East 12B Mayo Building, 200 First Street, Southwest, Rochester, MN 55905 0001, USA
    Gynecol Oncol 100:537-43. 2006
  4. ncbi Current research directions for locally advanced cervix cancer
    Harry J Long
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Oncol Rep 5:468-72. 2003
  5. ncbi Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium
    Harry J Long
    Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Gynecol Oncol 100:501-5. 2006
  6. ncbi Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: a Gynecologic Oncology Group study
    Harry J Long
    Department of Medical Oncology, Mayo Clinic College of Medicine, East 12B Mayo Building, 200 First Street, Southwest, Rochester, MN 55905 0001, USA
    Gynecol Oncol 99:339-42. 2005
  7. ncbi Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study
    Harry J Long
    Mayo Clinic College of Medicine, Rochester, MN, USA
    J Clin Oncol 23:4626-33. 2005
  8. ncbi Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisplatin with or without the addition of molgramostim, and review of the literature
    Harry J Long
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Am J Clin Oncol 25:547-51. 2002
  9. doi Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas
    Tina A Ayeni
    Division of Gynecologic Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Gynecol Oncol 129:478-85. 2013
  10. ncbi High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy
    Andrea Mariani
    Section of Gynecologic Surgery, Mayo Clinic, Rochester, MN 55905, USA
    Gynecol Oncol 95:120-6. 2004

Collaborators

Detail Information

Publications20

  1. ncbi Prevention, diagnosis, and treatment of cervical cancer
    Harry J Long
    Division of Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:1566-74. 2007
    ..Current recommendations for surgical treatment, concurrent chemotherapy, and radiation therapy and recent advances in systemic therapy for advanced or metastatic cervical cancer are reviewed...
  2. ncbi Management of metastatic cervical cancer: review of the literature
    Harry J Long
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA
    J Clin Oncol 25:2966-74. 2007
    ..This benefit is most apparent in patients who have a long disease-free interval from primary therapy and who have not received prior cisplatin as a radiosensitizer...
  3. ncbi Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study
    Harry J Long
    Mayo Clinic, Department of Medical Oncology, East 12B Mayo Building, 200 First Street, Southwest, Rochester, MN 55905 0001, USA
    Gynecol Oncol 100:537-43. 2006
    ..The primary endpoint was overall survival (OS), with response rate, progression-free survival (PFS), and quality of life (QOL) as secondary objectives...
  4. ncbi Current research directions for locally advanced cervix cancer
    Harry J Long
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Oncol Rep 5:468-72. 2003
    ..Well-designed, randomized, prospective clinical trials are needed for a more thorough evaluation of these preliminary findings and to set research directions for the next several years...
  5. ncbi Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium
    Harry J Long
    Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Gynecol Oncol 100:501-5. 2006
    ..The North Central Cancer Treatment Group Phase III trial compared efficacy of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) with doxorubicin plus cisplatin (AC) for patients with advanced endometrial cancer...
  6. ncbi Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: a Gynecologic Oncology Group study
    Harry J Long
    Department of Medical Oncology, Mayo Clinic College of Medicine, East 12B Mayo Building, 200 First Street, Southwest, Rochester, MN 55905 0001, USA
    Gynecol Oncol 99:339-42. 2005
    ....
  7. ncbi Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study
    Harry J Long
    Mayo Clinic College of Medicine, Rochester, MN, USA
    J Clin Oncol 23:4626-33. 2005
    ....
  8. ncbi Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisplatin with or without the addition of molgramostim, and review of the literature
    Harry J Long
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Am J Clin Oncol 25:547-51. 2002
    ..Its progression-free survival and overall survival rates appear promising. These results need to be confirmed within a large randomized phase III clinical trial...
  9. doi Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas
    Tina A Ayeni
    Division of Gynecologic Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Gynecol Oncol 129:478-85. 2013
    ..The objective of this study is to assess effects of clinicopathologic risk factors and contemporary therapeutic interventions on high-risk uterine epithelial carcinoma outcomes...
  10. ncbi High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy
    Andrea Mariani
    Section of Gynecologic Surgery, Mayo Clinic, Rochester, MN 55905, USA
    Gynecol Oncol 95:120-6. 2004
    ..To identify patients with endometrial cancer at risk for hematogenous, lymphatic, or peritoneal recurrence (or combinations of them) who might potentially benefit from target-based therapies...
  11. ncbi Multimodal therapy including neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for stage IIB to IV cervical cancer
    Sean C Dowdy
    Section of Gynecologic Surgery, Mayo Clinic, Rochester, MN 55905, USA
    Am J Obstet Gynecol 186:1167-73. 2002
    ....
  12. ncbi Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?
    Giovanni D Aletti
    Division of Gynecologic Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Gynecol Oncol 104:212-6. 2007
    ..Our objectives were to evaluate the correlation between clinical and pathologic variables and to evaluate the effect of the "time to chemotherapy" (TTC) interval on survival...
  13. pmc Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer
    Evanthia Galanis
    Division of Medical Oncology, Department of Molecular Medicine, Mayo Clinic, Gonda 10 141, 200 First Street Southwest, Rochester, MN 55905, USA
    Cancer Res 70:875-82. 2010
    ..Our findings indicate that i.p. administration of MV-CEA is well tolerated and results in dose-dependent biological activity in a cohort of heavily pretreated recurrent ovarian cancer patients...
  14. doi Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: brief report and review of the literature
    Mariam M Alhilli
    Department of Obstetrics and Gynecology Medical Oncology Obstetrics and Gynecology, Division of Gyencologic Oncology, Mayo Clinic, Rochester, Minnesota, USA
    J Obstet Gynaecol Res 38:340-4. 2012
    ..We present a heavily pre-treated, multi-operated patient who experienced significant tumor shrinkage following treatment with an aromatase inhibitor for her recurrent granulosa cell tumor...
  15. ncbi Second-line and subsequent therapy for ovarian carcinoma
    Prema P Peethambaram
    Division of Medical Oncology, Department of Oncology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    Curr Oncol Rep 4:159-64. 2002
    ..Whole abdominal radiotherapy for relapsed microscopic disease should be studied in prospective randomized trials. Women with advanced ovarian carcinoma should continue to be encouraged to participate in well-designed clinical trials...
  16. ncbi Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study
    George A Omura
    University of Alabama at Birmingham, Birmingham, AL, USA
    J Clin Oncol 21:2843-8. 2003
    ....
  17. ncbi Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group
    Mahesh A Varia
    Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
    J Clin Oncol 21:2849-55. 2003
    ....
  18. ncbi Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study
    Robert C Young
    Gynecologic Oncology Group, Administrative Office, Four Penn Center, 1600 John F Kennedy Blvd, Suite 1020, Philadelphia, PA 19103, USA
    J Clin Oncol 21:4350-5. 2003
    ..Materials and..
  19. ncbi Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study
    Bradley J Monk
    Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA, USA
    J Clin Oncol 23:4617-25. 2005
    ....
  20. ncbi A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma
    Ranjana Advani
    Oncology Division, Stanford University Medical Center, 269 Campus Drive, Stanford, CA 94305 5151, USA
    Cancer 100:321-6. 2004
    ..In a previous Phase I trial, the authors demonstrated the safety and some evidence of activity in ovarian carcinoma of aprinocarsen administered as a 21-day, continuous, intravenous infusion...